Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 62.66% year-on-year.
Undervalued
The company’s latest PE is -66.85, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 151.51M shares, decreasing 8.01% quarter-over-quarter.
Held by Andreas Halvorsen
Star Investor Andreas Halvorsen holds 30.08M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.99.